Giuseppe Piccolo
Overview
Explore the profile of Giuseppe Piccolo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marino M, Rosa A, Finocchietti M, Bellini A, Poggi F, Massari M, et al.
Front Transplant
. 2024 Jul;
1:1060621.
PMID: 38994384
Background: In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (), antimetabolites (), mammalian target of rapamycin inhibitors (), and corticosteroids. However, data on immunosuppressive therapy by...
2.
Bellini A, Finocchietti M, Rosa A, Nordio M, Ferroni E, Massari M, et al.
PLoS One
. 2024 Jan;
19(1):e0295205.
PMID: 38165971
Maintenance immunosuppressive therapy used in kidney transplantation typically involves calcineurin inhibitors, such as tacrolimus or cyclosporine, in combination with mycophenolate or mechanistic target of rapamycin (mTORi) with or without corticosteroids....
3.
Rosa A, Finocchietti M, Agabiti N, Mene P, Bracaccia M, Bellini A, et al.
BMC Nephrol
. 2023 Oct;
24(1):320.
PMID: 37891504
Background: Very scanty evidence is available on factors influencing the choice of immunosuppressive drug therapy after kidney transplantation. Methods: An Italian multiregional real-world study was conducted integrating national transplant information...
4.
Grossi A, Butti G, DE Min F, Donato M, Aurelio M, Carcano G, et al.
Minerva Anestesiol
. 2023 Sep;
90(1-2):101-103.
PMID: 37705434
No abstract available.
5.
Belleudi V, Rosa A, Finocchietti M, Poggi F, Marino M, Massari M, et al.
Front Pharmacol
. 2022 Oct;
13:959267.
PMID: 36188626
The goal of post-transplant immunosuppressive drug therapy is to prevent organ rejection while minimizing drug toxicities. In clinical practice, a multidrug approach is commonly used and involves drugs with different...
6.
Gregorini M, Ticozzelli E, Abelli M, Grignano M, Pattonieri E, Giacomoni A, et al.
Transpl Int
. 2022 Feb;
35:10179.
PMID: 35210934
Donation after circulatory death (DCD) allows expansion of the donor pool. We report on 11 years of Italian experience by comparing the outcome of grafts from DCD and extracorporeal membrane...
7.
Grossi A, Nicoli F, De Feo T, Cardillo M, Biffa G, Pegoraro R, et al.
Transplant Direct
. 2021 Oct;
7(11):e782.
PMID: 34712782
Background: The risk of disease transmission from nonstandard risk donors (NSRDs) is low, and outcomes are similar or better relative to transplants performed with standard criteria donors. However, NSRDs have...
8.
Mastroiacovo G, Guarino A, Pirola S, Gennari M, Capriuoli F, Micheli B, et al.
Cell Tissue Bank
. 2021 Sep;
22(4):675-683.
PMID: 34523044
The worldwide pandemic outbreak due to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has created unprecedented challenges for public health services. Lombardy, region of the Northern Italy, has been the first area...
9.
Passamonti S, Cannavo A, Panigada M, Trunzo V, Bottazzi A, Longobardi A, et al.
Transpl Int
. 2021 May;
34(7):1271-1280.
PMID: 34002900
Donations after circulatory death (DCD) are still challenging in Italy because of prolonged ischemia time (tWIT) due to the law and logistical issues. This cohort study was primarily aimed at...
10.
Maggi U, De Carlis L, Yiu D, Colledan M, Regalia E, Rossi G, et al.
Am J Transplant
. 2020 Apr;
20(7):1840-1848.
PMID: 32330351
In January 2020, Novel Coronavirus Disease 2019 (COVID-19) resulted in a global pandemic, creating uncertainty toward the management of liver transplantation (LT) programs. Lombardy has been the most affected region...